Comparison of the pathogenicity and neutrophil and monocyte response between SARS-CoV-2 prototype and Omicron BA.1 in a lethal mouse model

Abstract

Background: SARS-CoV-2, first identified in late 2019, has given rise to numerous variants of concern (VOCs), posing a significant threat to human health. The emergence of Omicron BA.1.1 towards the end of 2021 led to a pandemic in early 2022. At present, the lethal mouse model for the study of SARS-CoV-2 needs supplementation, and the alterations in neutrophils and monocytes caused by different strains remain to be elucidated.

Methods: Human ACE2 transgenic mice were inoculated with the SARS-CoV-2 prototype and Omicron BA.1, respectively. The pathogenicity of the two strains was evaluated by observing clinical symptoms, viral load and pathology. Complete blood count, immunohistochemistry and flow cytometry were performed to detect the alterations of neutrophils and monocytes caused by the two strains.

Results: Our findings revealed that Omicron BA.1 exhibited significantly lower virulence compared to the SARS-CoV-2 prototype in the mouse model. Additionally, we observed a significant increase in the proportion of neutrophils late in infection with the SARS-CoV-2 prototype and Omicron BA.1. We found that the proportion of monocytes increased at first and then decreased. The trends in the changes in the proportions of neutrophils and monocytes induced by the two strains were similar.

Conclusion: Our study provides valuable insights into the utility of mouse models for simulating the severe disease of SARS-CoV-2 prototype infection and the milder manifestation associated with Omicron BA.1. SARS-CoV-2 prototype and Omicron BA.1 resulted in similar trends in the changes in neutrophils and monocytes.

Keywords

animal model / SARS-CoV-2 / Omicron BA.1 / monocyte / neutrophil

References

[1] Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa. Nature. 2022; 603(7902): 679-686.

[2] Hyams C, Challen R, Marlow R, et al. Severity of omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023; 25: 100556.

[3] Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022; 7(1): 141.

[4] Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 omicron in China. Nat Med. 2022; 28(7): 1468-1475.

[5] COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022; 399(10334): 1513-1536.

[6] Néant N, Lingas G, Le Hingrat Q, et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci USA. 2021; 118(8): e2017962118.

[7] Hilgendorff A, Parai K, Ertsey R, et al. Neonatal mice genetically modified to express the elastase inhibitor elafin are protected against the adverse effects of mechanical ventilation on lung growth. Am J Physiol Lung Cell Mol Physiol. 2012; 303(3): L215-L227.

[8] Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020; 142(12): 1176-1189.

[9] Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020; 5(11): e138999.

[10] Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15): 762-768.

[11] Karimi A, Shobeiri P, Kulasinghe A, Rezaei N. Novel systemic inflammation markers to predict COVID-19 prognosis. Front Immunol. 2021; 12: 741061.

[12] Gómez-Rial J, Currás-Tuala MJ, Rivero-Calle I, et al. Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology. Front Immunol. 2020; 11: 560381.

[13] Shahbaz S, Bozorgmehr N, Lu J, et al. Analysis of SARS-CoV-2 isolates, namely the Wuhan strain, Delta variant, and omicron variant, identifies differential immune profiles. Microbiol Spectr. 2023; 11(5): e0125623.

[14] Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021; 590(7847): 635-641.

[15] Melms JC, Biermann J, Huang H, et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021; 595(7865): 114-119.

[16] Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020; 583(7818): 834-838.

[17] Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 omicron variant. Nature. 2022; 603(7902): 700-705.

[18] Yuan S, Ye ZW, Liang R, et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 omicron in Syrian hamsters. Science. 2022; 377(6604): 428-433.

[19] Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 omicron virus causes attenuated disease in mice and hamsters. Nature. 2022; 603(7902): 687-692.

[20] Zheng J, Wong LR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021; 589(7843): 603-607.

[21] Qi F, Qin C. Characteristics of animal models for COVID-19. Animal Model Exp Med. 2022; 5(5): 401-409.

[22] Uraki R, Kiso M, Iida S, et al. Characterization and antiviral susceptibility of SARS-CoV-2 omicron BA.2. Nature. 2022; 607(7917): 119-127.

[23] Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020; 84: 106504.

[24] Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020; 81(1): e6-e12.

[25] Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020; 52(5): 731-733.

[26] Kircheis R, Planz O. Could a lower toll-like receptor (TLR) and NF-κB activation due to a changed charge distribution in the spike protein be the reason for the lower pathogenicity of omicron? Int J Mol Sci. 2022; 23(11): 5966.

[27] Zhao Y, Kuang M, Li J, et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 2021; 31(7): 818-820.

[28] Shirato K, Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon. 2021; 7(2): e06187.

[29] Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020; 92(10): 2105-2113.

[30] Han P, Li L, Liu S, et al. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell. 2022; 185(4): 630-640.e610.

[31] Mulay SR, Anders HJ. Neutrophils and neutrophil extracellular traps regulate immune responses in health and disease. Cells. 2020; 9(9): 2130.

[32] Veras FP, Pontelli MC, Silva CM, et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med. 2020; 217(12): e20201129.

[33] Silva CMS, Wanderley CWS, Veras FP, et al. Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology. Crit Care. 2022; 26(1): 206.

[34] Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020; 182(6): 1419-1440.e1423.

[35] Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020; 26(7): 1070-1076.

[36] Lourda M, Dzidic M, Hertwig L, et al. High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. Proc Natl Acad Sci USA. 2021; 118(40): e2109123118.

[37] Lu T, Man Q, Yu X, et al. Development and validation of a prognostic model based on immune variables to early predict severe cases of SARS-CoV-2 omicron variant infection. Front Immunol. 2023; 14: 1157892.

[38] Bay P, Rodriguez C, Caruso S, et al. Omicron induced distinct immune respiratory transcriptomics signatures compared to pre-existing variants in critically ill COVID-19 patients. J Med Virol. 2023; 95(12): e29268.

[39] Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J. Reduced interferon antagonism but similar drug sensitivity in omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res. 2022; 32(3): 319-321.

[40] Evrard M, Kwok IWH, Chong SZ, et al. Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. Immunity. 2018; 48(2): 364-379.e368.

[41] Tvedten HW, Andersson V, Lilliehöök IE. Feline differential leukocyte count with ProCyte dx: frequency and severity of a neutrophil-lymphocyte error and how to avoid it. J Vet Intern Med. 2017; 31(6): 1708-1716.

[42] Lilliehöök I, Tvedten H. Validation of the Sysmex XT-2000iV hematology system for dogs, cats, and horses. II. Differential leukocyte counts. Vet Clin Pathol. 2009; 38(2): 175-182.

[43] Bauer N, Nakagawa J, Dunker C, Failing K, Moritz A. Evaluation of the automated hematology analyzer Sysmex XT-2000iV™ compared to the ADVIA® 2120 for its use in dogs, cats, and horses. Part II: accuracy of leukocyte differential and reticulocyte count, impact of anticoagulant and sample aging. J Vet Diagn Invest. 2012; 24(1): 74-89.

[44] Unterman A, Sumida TS, Nouri N, et al. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat Commun. 2022; 13(1): 440.

RIGHTS & PERMISSIONS

2024 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.